Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection
Lung cancer is the leading worldwide cancer with almost 1.5 million deaths every year. Some drugs for lung cancer treatment have been available on the market for decades, but novel drugs have emerged promising better outcomes, especially for Non-Small Cell Lung Cancer (NSCLC), which represents 75% o...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Ruiz-Ceja, Karla A. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
14 |
|---|
| Übergeordnetes Werk: |
Enthalten in: A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a - Liao, Gary ELSEVIER, 2020, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:90 ; year:2017 ; pages:24-37 ; extent:14 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.biopha.2017.03.018 |
|---|
| Katalog-ID: |
ELV015177637 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV015177637 | ||
| 003 | DE-627 | ||
| 005 | 20230623121305.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2017.03.018 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000092A.pica |
| 035 | |a (DE-627)ELV015177637 | ||
| 035 | |a (ELSEVIER)S0753-3322(17)30049-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.86 |2 bkl | ||
| 100 | 1 | |a Ruiz-Ceja, Karla A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection |
| 264 | 1 | |c 2017 | |
| 300 | |a 14 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Lung cancer is the leading worldwide cancer with almost 1.5 million deaths every year. Some drugs for lung cancer treatment have been available on the market for decades, but novel drugs have emerged promising better outcomes, especially for Non-Small Cell Lung Cancer (NSCLC), which represents 75% of lung cancer cases. However, how much do drugs have evolved for NSCLC treatment? Are they sharing the same mechanism of action? | ||
| 650 | 7 | |a Non-small cell lung cancer |2 Elsevier | |
| 650 | 7 | |a Biomarkers |2 Elsevier | |
| 650 | 7 | |a Federal drug agency |2 Elsevier | |
| 650 | 7 | |a Lung cancer treatment |2 Elsevier | |
| 700 | 1 | |a Chirino, Yolanda I. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Liao, Gary ELSEVIER |t A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a |d 2020 |g Amsterdam [u.a.] |w (DE-627)ELV004620771 |
| 773 | 1 | 8 | |g volume:90 |g year:2017 |g pages:24-37 |g extent:14 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.biopha.2017.03.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.86 |j Hämatologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 90 |j 2017 |h 24-37 |g 14 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
k a r c kar karc |
|---|---|
| matchkey_str |
ruizcejakarlaachirinoyolandai:2017----:urnfaprvdramnsonnmlcllncneadoetab |
| hierarchy_sort_str |
2017 |
| bklnumber |
44.86 |
| publishDate |
2017 |
| allfields |
10.1016/j.biopha.2017.03.018 doi GBV00000000000092A.pica (DE-627)ELV015177637 (ELSEVIER)S0753-3322(17)30049-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.86 bkl Ruiz-Ceja, Karla A. verfasserin aut Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection 2017 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Lung cancer is the leading worldwide cancer with almost 1.5 million deaths every year. Some drugs for lung cancer treatment have been available on the market for decades, but novel drugs have emerged promising better outcomes, especially for Non-Small Cell Lung Cancer (NSCLC), which represents 75% of lung cancer cases. However, how much do drugs have evolved for NSCLC treatment? Are they sharing the same mechanism of action? Non-small cell lung cancer Elsevier Biomarkers Elsevier Federal drug agency Elsevier Lung cancer treatment Elsevier Chirino, Yolanda I. oth Enthalten in Elsevier Science Liao, Gary ELSEVIER A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a 2020 Amsterdam [u.a.] (DE-627)ELV004620771 volume:90 year:2017 pages:24-37 extent:14 https://doi.org/10.1016/j.biopha.2017.03.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.86 Hämatologie VZ AR 90 2017 24-37 14 045F 610 |
| spelling |
10.1016/j.biopha.2017.03.018 doi GBV00000000000092A.pica (DE-627)ELV015177637 (ELSEVIER)S0753-3322(17)30049-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.86 bkl Ruiz-Ceja, Karla A. verfasserin aut Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection 2017 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Lung cancer is the leading worldwide cancer with almost 1.5 million deaths every year. Some drugs for lung cancer treatment have been available on the market for decades, but novel drugs have emerged promising better outcomes, especially for Non-Small Cell Lung Cancer (NSCLC), which represents 75% of lung cancer cases. However, how much do drugs have evolved for NSCLC treatment? Are they sharing the same mechanism of action? Non-small cell lung cancer Elsevier Biomarkers Elsevier Federal drug agency Elsevier Lung cancer treatment Elsevier Chirino, Yolanda I. oth Enthalten in Elsevier Science Liao, Gary ELSEVIER A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a 2020 Amsterdam [u.a.] (DE-627)ELV004620771 volume:90 year:2017 pages:24-37 extent:14 https://doi.org/10.1016/j.biopha.2017.03.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.86 Hämatologie VZ AR 90 2017 24-37 14 045F 610 |
| allfields_unstemmed |
10.1016/j.biopha.2017.03.018 doi GBV00000000000092A.pica (DE-627)ELV015177637 (ELSEVIER)S0753-3322(17)30049-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.86 bkl Ruiz-Ceja, Karla A. verfasserin aut Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection 2017 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Lung cancer is the leading worldwide cancer with almost 1.5 million deaths every year. Some drugs for lung cancer treatment have been available on the market for decades, but novel drugs have emerged promising better outcomes, especially for Non-Small Cell Lung Cancer (NSCLC), which represents 75% of lung cancer cases. However, how much do drugs have evolved for NSCLC treatment? Are they sharing the same mechanism of action? Non-small cell lung cancer Elsevier Biomarkers Elsevier Federal drug agency Elsevier Lung cancer treatment Elsevier Chirino, Yolanda I. oth Enthalten in Elsevier Science Liao, Gary ELSEVIER A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a 2020 Amsterdam [u.a.] (DE-627)ELV004620771 volume:90 year:2017 pages:24-37 extent:14 https://doi.org/10.1016/j.biopha.2017.03.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.86 Hämatologie VZ AR 90 2017 24-37 14 045F 610 |
| allfieldsGer |
10.1016/j.biopha.2017.03.018 doi GBV00000000000092A.pica (DE-627)ELV015177637 (ELSEVIER)S0753-3322(17)30049-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.86 bkl Ruiz-Ceja, Karla A. verfasserin aut Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection 2017 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Lung cancer is the leading worldwide cancer with almost 1.5 million deaths every year. Some drugs for lung cancer treatment have been available on the market for decades, but novel drugs have emerged promising better outcomes, especially for Non-Small Cell Lung Cancer (NSCLC), which represents 75% of lung cancer cases. However, how much do drugs have evolved for NSCLC treatment? Are they sharing the same mechanism of action? Non-small cell lung cancer Elsevier Biomarkers Elsevier Federal drug agency Elsevier Lung cancer treatment Elsevier Chirino, Yolanda I. oth Enthalten in Elsevier Science Liao, Gary ELSEVIER A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a 2020 Amsterdam [u.a.] (DE-627)ELV004620771 volume:90 year:2017 pages:24-37 extent:14 https://doi.org/10.1016/j.biopha.2017.03.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.86 Hämatologie VZ AR 90 2017 24-37 14 045F 610 |
| allfieldsSound |
10.1016/j.biopha.2017.03.018 doi GBV00000000000092A.pica (DE-627)ELV015177637 (ELSEVIER)S0753-3322(17)30049-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.86 bkl Ruiz-Ceja, Karla A. verfasserin aut Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection 2017 14 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Lung cancer is the leading worldwide cancer with almost 1.5 million deaths every year. Some drugs for lung cancer treatment have been available on the market for decades, but novel drugs have emerged promising better outcomes, especially for Non-Small Cell Lung Cancer (NSCLC), which represents 75% of lung cancer cases. However, how much do drugs have evolved for NSCLC treatment? Are they sharing the same mechanism of action? Non-small cell lung cancer Elsevier Biomarkers Elsevier Federal drug agency Elsevier Lung cancer treatment Elsevier Chirino, Yolanda I. oth Enthalten in Elsevier Science Liao, Gary ELSEVIER A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a 2020 Amsterdam [u.a.] (DE-627)ELV004620771 volume:90 year:2017 pages:24-37 extent:14 https://doi.org/10.1016/j.biopha.2017.03.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.86 Hämatologie VZ AR 90 2017 24-37 14 045F 610 |
| language |
English |
| source |
Enthalten in A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a Amsterdam [u.a.] volume:90 year:2017 pages:24-37 extent:14 |
| sourceStr |
Enthalten in A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a Amsterdam [u.a.] volume:90 year:2017 pages:24-37 extent:14 |
| format_phy_str_mv |
Article |
| bklname |
Hämatologie |
| institution |
findex.gbv.de |
| topic_facet |
Non-small cell lung cancer Biomarkers Federal drug agency Lung cancer treatment |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a |
| authorswithroles_txt_mv |
Ruiz-Ceja, Karla A. @@aut@@ Chirino, Yolanda I. @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV004620771 |
| dewey-sort |
3610 |
| id |
ELV015177637 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV015177637</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623121305.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.biopha.2017.03.018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000092A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV015177637</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0753-3322(17)30049-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.86</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ruiz-Ceja, Karla A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">14</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Lung cancer is the leading worldwide cancer with almost 1.5 million deaths every year. Some drugs for lung cancer treatment have been available on the market for decades, but novel drugs have emerged promising better outcomes, especially for Non-Small Cell Lung Cancer (NSCLC), which represents 75% of lung cancer cases. However, how much do drugs have evolved for NSCLC treatment? Are they sharing the same mechanism of action?</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Non-small cell lung cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biomarkers</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Federal drug agency</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lung cancer treatment</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chirino, Yolanda I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Liao, Gary ELSEVIER</subfield><subfield code="t">A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV004620771</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:90</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:24-37</subfield><subfield code="g">extent:14</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.biopha.2017.03.018</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.86</subfield><subfield code="j">Hämatologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">90</subfield><subfield code="j">2017</subfield><subfield code="h">24-37</subfield><subfield code="g">14</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Ruiz-Ceja, Karla A. |
| spellingShingle |
Ruiz-Ceja, Karla A. ddc 610 bkl 44.86 Elsevier Non-small cell lung cancer Elsevier Biomarkers Elsevier Federal drug agency Elsevier Lung cancer treatment Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection |
| authorStr |
Ruiz-Ceja, Karla A. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV004620771 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.86 bkl Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection Non-small cell lung cancer Elsevier Biomarkers Elsevier Federal drug agency Elsevier Lung cancer treatment Elsevier |
| topic |
ddc 610 bkl 44.86 Elsevier Non-small cell lung cancer Elsevier Biomarkers Elsevier Federal drug agency Elsevier Lung cancer treatment |
| topic_unstemmed |
ddc 610 bkl 44.86 Elsevier Non-small cell lung cancer Elsevier Biomarkers Elsevier Federal drug agency Elsevier Lung cancer treatment |
| topic_browse |
ddc 610 bkl 44.86 Elsevier Non-small cell lung cancer Elsevier Biomarkers Elsevier Federal drug agency Elsevier Lung cancer treatment |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
y i c yi yic |
| hierarchy_parent_title |
A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a |
| hierarchy_parent_id |
ELV004620771 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV004620771 |
| title |
Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection |
| ctrlnum |
(DE-627)ELV015177637 (ELSEVIER)S0753-3322(17)30049-5 |
| title_full |
Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection |
| author_sort |
Ruiz-Ceja, Karla A. |
| journal |
A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a |
| journalStr |
A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
24 |
| author_browse |
Ruiz-Ceja, Karla A. |
| container_volume |
90 |
| physical |
14 |
| class |
610 610 DE-600 610 VZ 44.86 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Ruiz-Ceja, Karla A. |
| doi_str_mv |
10.1016/j.biopha.2017.03.018 |
| dewey-full |
610 |
| title_sort |
current fda-approved treatments for non-small cell lung cancer and potential biomarkers for its detection |
| title_auth |
Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection |
| abstract |
Lung cancer is the leading worldwide cancer with almost 1.5 million deaths every year. Some drugs for lung cancer treatment have been available on the market for decades, but novel drugs have emerged promising better outcomes, especially for Non-Small Cell Lung Cancer (NSCLC), which represents 75% of lung cancer cases. However, how much do drugs have evolved for NSCLC treatment? Are they sharing the same mechanism of action? |
| abstractGer |
Lung cancer is the leading worldwide cancer with almost 1.5 million deaths every year. Some drugs for lung cancer treatment have been available on the market for decades, but novel drugs have emerged promising better outcomes, especially for Non-Small Cell Lung Cancer (NSCLC), which represents 75% of lung cancer cases. However, how much do drugs have evolved for NSCLC treatment? Are they sharing the same mechanism of action? |
| abstract_unstemmed |
Lung cancer is the leading worldwide cancer with almost 1.5 million deaths every year. Some drugs for lung cancer treatment have been available on the market for decades, but novel drugs have emerged promising better outcomes, especially for Non-Small Cell Lung Cancer (NSCLC), which represents 75% of lung cancer cases. However, how much do drugs have evolved for NSCLC treatment? Are they sharing the same mechanism of action? |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection |
| url |
https://doi.org/10.1016/j.biopha.2017.03.018 |
| remote_bool |
true |
| author2 |
Chirino, Yolanda I. |
| author2Str |
Chirino, Yolanda I. |
| ppnlink |
ELV004620771 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1016/j.biopha.2017.03.018 |
| up_date |
2024-07-06T16:58:02.369Z |
| _version_ |
1803849650533302272 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV015177637</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623121305.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.biopha.2017.03.018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000092A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV015177637</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0753-3322(17)30049-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.86</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ruiz-Ceja, Karla A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">14</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Lung cancer is the leading worldwide cancer with almost 1.5 million deaths every year. Some drugs for lung cancer treatment have been available on the market for decades, but novel drugs have emerged promising better outcomes, especially for Non-Small Cell Lung Cancer (NSCLC), which represents 75% of lung cancer cases. However, how much do drugs have evolved for NSCLC treatment? Are they sharing the same mechanism of action?</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Non-small cell lung cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biomarkers</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Federal drug agency</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Lung cancer treatment</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chirino, Yolanda I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Liao, Gary ELSEVIER</subfield><subfield code="t">A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV004620771</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:90</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:24-37</subfield><subfield code="g">extent:14</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.biopha.2017.03.018</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.86</subfield><subfield code="j">Hämatologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">90</subfield><subfield code="j">2017</subfield><subfield code="h">24-37</subfield><subfield code="g">14</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4021015 |